Advanced Search
Contact | Corporate | Help

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Sponsors:
  • Genentech
  • Sarah Cannon Research Institute
Phases:
  • Phase II
IndicationsAcronym:
  • Colorectal Cancer
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: onartuzumab [MetMAb]
  • Drug: Placebo
  • Drug: bevacizumab [Avastin]
  • Drug: FOLFOX regimen
  • Drug: leucovorin
  • Drug: 5-FU
Enrollment:
188

Additional information about NCT01418222.


SourceSolution © 2008-2012